Detalhe da pesquisa
1.
Tumor-stroma ratio is associated with Miller-Payne score and pathological response to neoadjuvant chemotherapy in HER2-negative early breast cancer.
Int J Cancer
; 149(5): 1181-1188, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34043821
2.
Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer.
Breast Cancer Res Treat
; 168(2): 413-420, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29230665
3.
Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis.
Acta Oncol
; 54(3): 349-60, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25383451
4.
Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy.
Clin Cancer Res
; 27(1): 311-319, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33109739
5.
Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.
J Clin Oncol
; 38(28): 3273-3281, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32706636
6.
Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.
Eur J Cancer
; 95: 59-67, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29635145
7.
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
J Natl Cancer Inst
; 110(1)2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28922787